Researchers have discovered in a new study that using Paxlovid (nirmatrelvir/ritonavir) early in the course of ...

Pfizer’s first-quarter revenue missed analyst estimates as it faces an “uncertain and volatile external environment.” ...

Merck & Co. is undervalued with strong oncology growth, key R&D investments, and shareholder returns. Click here to read an ...

A widely available antiviral medication offers new possibilities for long Covid patients seeking relief from debilitating symptoms. Research shows extended Paxlovid treatment could help restore ...

The risk for COVID-19-related hospitalization was not significantly different between vaccinated older adults with vs without age-restrictive access to nirmatrelvir-ritonavir.

President Joe Biden's "aggressive" prostate cancer has led to renewed interest in his health during his presidency ...

An infectious diseases specialist separates fact from fiction, powering us with information about symptoms, treatments, precautions and more ...

The antiviral, also known as Paxlovid, is no longer cost effective in the over-70s as well as people with diabetes, obesity and heart failure, the new recommendations said. It follows a partial review ...

although it fell short of Wall Street’s revenue estimate, as sales of its COVID-19 medicine Paxlovid plunged by 75% on fading demand. Back To Top ...

These four quality stocks trading at or near their 52-week lows come with stellar dividends that could be massive bargains ...

Research indicates that high-yield stock portfolios outperform over time. Does your portfolio have the right mix of ...